(Q46308015)

21 December 2017

title

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib (English)

1 reference

21 December 2017

1 reference

2

1 reference

21 December 2017

Patrick Hwu

6

object named as

Patrick Hwu

1 reference

21 December 2017

author name string

Alfonso Quintás-Cardama

1

1 reference

21 December 2017

Scott E Woodman

3

1 reference

21 December 2017

Kevin Kim

4

1 reference

21 December 2017

Merrick Ross

5

1 reference

21 December 2017

publication date

21 October 2008

1 reference

21 December 2017

Nature Clinical Practice Oncology

published in

1 reference

21 December 2017

volume

5

1 reference

21 December 2017

issue

12

1 reference

21 December 2017

page(s)

737-740

1 reference

21 December 2017

Epidemiology and prognosis of anorectal melanoma

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Anorectal melanoma--an incurable disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Biochemotherapy in patients with metastatic anorectal mucosal melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Prevalence of KIT expression in human tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Mutations in gastrointestinal stromal tumors--a population-based study from Northern Norway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1251

7 January 2021

Identifiers

DOI

10.1038/NCPONC1251

1 reference

21 December 2017

1 reference

21 December 2017